Global Quadrivalent Market Segments 2024, Forecast To 2033
5 Mar, 2024
The quadrivalent market has shown strong growth, increasing from $8.28 billion in 2023 to $8.98 billion in 2024, with an 8.4% CAGR. Drivers include disease complexity, educational initiatives, and technological progress. The forecast envisions sustained growth, reaching $12.88 billion in 2028, with a 9.4% CAGR. Key trends involve disease prevalence, regulatory changes, healthcare infrastructure, consumer awareness, and education.
Global Quadrivalent Market Key Driver
The quadrivalent market is thriving due to the rising prevalence of chronic and infectious diseases. Chronic diseases claim millions of lives annually, with infectious diseases causing substantial morbidity. Quadrivalent vaccines play a crucial role in preventing infections and associated chronic diseases. The World Health Organization's data underscores the impact of chronic and infectious diseases on global health, highlighting the significance of quadrivalent vaccines.
Get A Free Sample Of The Global Quadrivalent Market ReportGlobal Quadrivalent Market Segments
The quadrivalent market covered in this report is segmented –
1) By Type: Intradermal Shot, Intramuscular Injection, Nasal Spray
2) By Technology: Conjugated, Live, Inactivated, Recombinant, Toxoid, Other Technologies
3) By Disease: Cancer, Hepatitis, Pneumococcal disease, COVID-19, Influenza, Human Papilloma Virus, Meningococcal Disease, Polio, Rotavirus, Other Diseases
4) By Age Group: Pediatric, Adult
5) By Distribution Channel: Hospital And Pharmacy, Government Suppliers, Other Channels (NGOs)
By Geography: The regions covered in the anti inflammatory therapeutics market report are Asia-Pacific, Western Europe, Eastern Europe,North America, South America, Middle East, and Africa. Among these regions.
North America was the largest region in the quadrivalent market in 2023. The regions covered in the quadrivalent market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa
Major Quadrivalent Industry Players
AstraZeneca Plc; Serum Institute of India Private Limited; Sanofi S.A.; GlaxoSmithKline Plc; CSL Limited; Bharat Biotech International Limited; Hualan Biological Engineering Inc.; Merck & Co. Inc.; Johnson & Johnson Services Inc.; Novartis AG; Pfizer Inc.; Xenetic Biosciences Inc.; Bio Med Pvt. Ltd.; Walvax Biotechnology Co. Ltd.; Chongqing Zhifei Biological Products Co. Ltd.; Hoffmann-La Roche Ltd.; Gamma Vaccines Pty Ltd.; Biodiem Ltd.; Emergent BioSolutions Inc.; Biological E. Limited; GSK Biologicals SA; Institute of Vaccines and Biological Products Chinese Academy of Medical Sciences; Wuhan Institute of Biological Products Co. Ltd.; Beijing Tian Tan Biological Products Co. Ltd.; Shanghai Zhijiang Bio-pharm Co. Ltd.; MedImmune; Bio Farma; Butantan Institute; Pasteur Institute of India; China National Biotec Group Co. Ltd. (CNBG)
Get The Full Global Quadrivalent Market Report
AIOps Quadrivalent Market Overview
Quadrivalent is a vaccination that stimulates the immune system to respond to distinct antigens, such as four different viruses or bacteria. A quadrivalent vaccination is intended to protect against four distinct flu viruses, two of which are type A and type B.
Quadrivalent Global Market Report 2023 provides data on the global quadrivalent market such as market size, growth forecasts, segments and geographies, competitive landscape including leading competitors’ revenues, profiles and market shares. The quadrivalent market report identifies opportunities and strategies based on market trends and leading competitors’ approaches.